Literature DB >> 16013989

Lamotrigine in the treatment of bipolar disorder.

Zubin Bhagwagar1, Guy M Goodwin.   

Abstract

Lamotrigine is a novel anticonvulsant agent that has recently been introduced as a long-term treatment in bipolar disorder. Its role in the treatment of epilepsy is based on its actions to decrease ion channel conductance and antagonise glutamatergic function. Therefore, it has a mode of action unlike other agents used on a long-term basis in mood disorders. The evidence for efficacy is stronger for the prevention of depressive, rather than manic, episodes. The pivotal trials are in bipolar I disorder, but there is interest in its actions in patients with bipolar II and spectrum conditions. Its efficacy in other psychiatric conditions remains to be properly established. It is well tolerated and, with careful prescribing, the incidence of rash occurs no more than with placebo; however this is still a concern. Although usually well tolerated, headache, insomnia and drowsiness are probably the most common side effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16013989     DOI: 10.1517/14656566.6.8.1401

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  4 in total

Review 1.  Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

Authors:  Cagri Yüksel; Dost Öngür
Journal:  Biol Psychiatry       Date:  2010-08-21       Impact factor: 13.382

Review 2.  Novel glutamatergic agents for major depressive disorder and bipolar disorder.

Authors:  Rodrigo Machado-Vieira; Lobna Ibrahim; Ioline D Henter; Carlos A Zarate
Journal:  Pharmacol Biochem Behav       Date:  2011-09-25       Impact factor: 3.533

Review 3.  The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.

Authors:  Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Neuroscientist       Date:  2009-05-26       Impact factor: 7.519

4.  Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor.

Authors:  Piero Mannu; Salvatore Rinaldi; Vania Fontani; Alessandro Castagna
Journal:  Neuropsychiatr Dis Treat       Date:  2011-06-15       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.